©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Aggregation of the FcRI in Mast Cells Induces the Synthesis of Fos-interacting Protein and Increases Its DNA Binding Activity: The Dependence on Protein Kinase C- (*)

(Received for publication, October 9, 1995; and in revised form, November 7, 1995)

Iris Lewin (1) Jasmine Jacob-Hirsch (1) Zhao Cheng Zang (1) Valentina Kupershtein (1) Zoltan Szallasi (2) Juan Rivera (3) Ehud Razin (1)(§)

From the  (1)Department of Biochemistry Hebrew University, Hadassah Medical School, P. O. Box 12272, Jerusalem 91120, Israel and the (2)Laboratory of Cellular Carcinogenesis and Tumor Promotion, NCI and (3)the Section on Chemical Immunology, NIAMS, National Institutes of Health, Bethesda, Maryland 20892

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

The ability of c-Fos to dimerize with various proteins creates transcription complexes which can exert their regulatory function on a variety of genes. One of the transcription factors that binds to c-Fos is the newly discovered Fos-interacting protein (FIP). In this report we present evidence for the regulation of the synthesis of FIP by a physiological stimulus. We found that the aggregation of the mast cell high affinity receptor for IgE (FcRI) induced the synthesis of FIP and increased its DNA binding activity. Moreover, down-regulation of the isoenzyme protein kinase C-beta (PKC-beta) by a specific antisense phosphorothioate oligonucleotide resulted in profound inhibition of FIP-Fos DNA binding activity. Thus, aggregation of the FcRI on mast cells elicits a PKC-beta dependent signaling pathway which regulates FIP-Fos DNA binding activity.


INTRODUCTION

IgE-antigen (IgE-Ag)(^1)-mediated activation of mast cells results in the phosphorylation of the cell surface IgE Fc receptor (FcRI), priming the receptor for direct interactions with effector molecules that initiate diverse signal transduction pathways (1) . These signaling pathways ultimately lead to the release of mast cell granule contents and the activation of genes encoding inflammatory products.

Some of these genes are known to be regulated by AP-1 activity(2, 3) . The AP-1 is a complex of transcription factor proteins which play an important role in mitosis and, in particular, the entry of cells into S phase(4, 5, 6) . The AP-1 is comprised of a Jun homodimer or a Fos-Jun heterodimer. The Fos protein was found to be incapable of forming a homodimer but rapidly forms a highly stable complex via a leucine zipper interaction with the Jun protein or with selected members of the family of activating transcription factor/cAMP-responsive element-binding proteins(7) . As a heterodimer, Fos and Jun activate transcription through the AP-1 binding site found in the promoter region of a variety of genes(2, 3) . The binding of this heterodimer to its DNA binding site may in part be regulated by the phosphorylation of Jun. The phosphorylation of Jun requires both mitogen-activated protein kinase and protein kinase C (PKC) activities(8) . Recently we found that the aggregation of the FcRI, on the interleukin-3-dependent murine fetal liver derived mast cells (MC-9), increased the AP-1 DNA binding activity in these cells, a process found to be dependent on PKC activity. We also found that in IgE antigen-activated MC-9 cells most of the newly synthesized c-Fos was bound to proteins other than Jun.

The USF family represents one class of proteins which can interact with Fos(9) . The protein product of USF-2 is generally referred to as Fos-interacting protein (FIP)(10, 11) . Members of this family recognize the DNA sequence of CACGTG(10) . They are also characterized by the leucine zipper (Zip) and the helix-loop-helix (HLH) dimerization motifs that are found in various eukaryotic transcription factors and makes these proteins members of the basic region Zip (bZip) and/or basic region HLH (bHLH) families. Family members include TFE3, USF-1, USF-2, TFEB, AP-4, Myc, and Max(11) . The presence of the bHLH/Zip functional domains permits the formation of homodimers and heterodimers among the family members. The formation of these complexes may be regulated by protein kinase activity(8) .

Protein kinase C regulatory enzymes have been implicated in physiological processes such as membrane receptor function, cell differentiation, and proliferation(12) . The functional diversity of PKC may in part be mediated by distinct isoenzymes that play an important role in both the activation and regulation of signaling pathways in the cell. Recent studies in rat basophilic leukemia cells, a rat analog of mucosal mast cells, begin to explore the role of these isoenzymes in mast cell function. Ozawa et al. (13) found that a full secretory response to antigen could be reconstituted by either PKC-beta or -, but not by PKC-alpha or -. Our own experiments, in these cells, showed that the increased activity of PKC-beta and -, activated by the aggregation of the FcRI, resulted in the induction of c-Fos and c-Jun mRNA synthesis(14) . Recently we also observed a PKC-dependent increase in the binding of the FIP-Fos complex to its target DNA in response to the aggregation of the FcRI(9) . In the present study we assess the relationship between the aggregation of the FcRI, activation of PKC isoenzyme activity, synthesis of FIP protein, and the FIP-Fos DNA binding activity.


MATERIALS AND METHODS

Cell Culture

MC-9 cells(15) , obtained from the American Type Culture Collection (Rockville, MD), were maintained in RPMI 1640 supplemented with 2 mML-glutamine, 2 mM nonessential amino acids, 100 units/ml penicillin, 100 mg/ml streptomycin (Life Technologies, Inc.), 50 mM beta-mercaptoethanol (Fisher), 10% fetal calf serum (Bio-Lab, Jerusalem), and 20% WEHI-3 conditioned medium. Human KU812 cells, obtained from the American Type Culture Collection (Rockville, Maryland), were maintained in the same MC-9 cultured medium, however, without the WEHI-3 conditioned medium(16) .

Treatments of Cells with Phosphorothioate Oligodeoxynucleotide

The MC-9 cells were incubated for 6 h in the presence or the absence of 20 ng PMA/ml. Cells were then washed and transferred to flat bottom 24-well plates (Nunc, Denmark) at a density of 1 times 10^6 cells/well in growth medium containing or not either 10 µM sense or antisense phosphorothioate oligodeoxynucleotide specific to the mouse calcium-dependent isoforms of PKC (c-PKC). The cells were then incubated at 37 °C in 5% CO(2), and after 24 h a second addition of 10 µM of oligonucleotides was made. This was followed by an additional 24-h incubation prior to triggering of the cells with IgE-Ag. In some experiments the cells were washed three times after the oligonucleotide treatment and incubated with only growth medium for 24 h at 37 °C prior to triggering with IgE-Ag. The oligonucleotides used were from the mouse c-PKC nucleotide sequence. The sense oligonucleotide was: 5`-GTACGAGATGCAAAAAAT-3` and the antisense oligonucleotide was: 5`-ATTTTTTGCATCTCGTAC-3` corresponding to bases 577-594, respectively (17) .

IgE-Ag Stimulation of Mast Cells

MC-9 cells were transferred to serum-free RPMI medium. IgE sensitization was carried out by incubating duplicates of 2.5 times 10^6 cells/well with 2.5 µg of monoclonal IgE against dinitrophenol (DNP) (kindly provided by Dr. F.-T. Liu, La Jolla, CA) for 45 min at 37 °C in a final volume of 200 µl of modified Tyrode's solution containing 1.0 mM Ca, 0.3 mM Mg, and 1 mg/ml gelatin (TG). The cells were then incubated at 37 °C with 250 ng of DNP coupled to bovine serum albumin (DNP-BSA) for defined periods of time. Cells were quenched by washing in cold TG and recovered by centrifugation. Cell viability before and after each experiment was greater than 95%, as determined by trypan blue exclusion.

Immunoblotting of PKC Isoenzymes

To assess the effect of the phosphorothioate oligonucleotides on PKC isozymes the treated cells were washed with saline and immediately solubilized by the addition of boiling Tricine-SDS sample buffer (Novex, Encinitas, CA) directly in the culture dishes. In a duplicate sample the cell number was determined. Proteins from the cell extracts were separated by electrophoresis on 10% Tricine-SDS gels and transferred to nitrocellulose membrane. Protein kinase C isoenzymes were detected as follows: Two mg/ml of mouse monoclonal antibodies to the catalytic domain of PKC-alpha (Upstate Biotechnology, Inc., Lake Placid, NY) or of PKC-beta (Seikagaku Corp, Tokyo, Japan) were used. An affinity-purified rabbit polyclonal antibody to the C terminus of rat PKC- (Research & Diagnostics Antibodies, Berkeley, CA) was used at 1:50,000 dilution. Rabbit polyclonal antibody to the C terminus of rat PKC- (Santa Cruz Biotech, Santa Cruz, CA) was used at 1:100 dilution. The specificity of the antibodies used was confirmed using baculovirus expressed PKC-alpha, -beta, -, -, -, and -. Individual blots were incubated with the appropriate antibody overnight at 37 °C in 4% milk phosphate-buffered saline. The immunoreactive proteins were detected using a species-specific, horseradish peroxidase-conjugated secondary antibody (Bio-Rad). Quantitation was as described previously using known concentrations of baculovirus expressed isoenzymes as standards (18) . The software NIH Image 1.52 (written by Dr. Wayne Raspband, National Institutes of Health) was used for analysis of densitometric scans.

MC-9 cDNA Library and DNA Sequencing

A cDNA library derived from IgE-Ag-stimulated MC-9 cells was prepared in the Zap vector (Stratagene). Screening of this library was by use of a polymerase chain reaction-generated probe derived from the human nucleotide sequence of FIP. The probe is a 284-base pair oligonucleotide fragment derived from the 3` region of the human FIP cDNA(11) . Primers used were: sense, 5`-AGG AGA AGA GCC CAG CAC AAC-3`, corresponding to bases 427-448; and antisense, 5`-TCG AAG CAG GGC GTT CTC ATT CTT-3`, corresponding to bases 688-711. Five identical clones were isolated from 15 times 10^3 plaques screened. DNA sequencing was by the dideoxy termination method using double strand DNA templates and Sequenase (19) and clone-specific primers.

Preparation of Rabbit Anti-mouse FIP Antibody

A synthetic 14-amino acid peptide, QQHNLEMVGESTRQ, corresponding to the amino acid sequence encoded by the base pairs 180-216 of the open reading frame of the cloned mouse FIP was synthesized as a eight-branched peptide on multiple antigen peptide resin (ABI, Foster City, CA). A search of the SwissProt Data Bank for FIP peptide homology did not reveal a protein with greater than 20% homology to this peptide. The primary immunization of rabbits was intramuscular with subsequent subcutaneous immunizations of 1 mg of peptide mixed with RIBI adjuvant (RIBI ImmunoChem Research, Inc.). Rabbits were boosted two times in 14-day intervals with the same amount of peptide. Seven days after the last boost animals were bled, and the presence of antibodies to FIP was determined.

Serum antibodies to the synthetic peptide were assayed by enzyme-linked immunosorbent assay using 20 mg of peptide and 2 mg of BSA as control per well. Both preimmune and immune sera were diluted by serial 10-fold dilutions to a final of 10. The end point titer was defined as the immune serum dilution that gave values of absorbance of at least 0.2, these values were 10 times higher than the mean background absorbance for BSA. Detection of bound antibody was by using anti-rabbit IgG coupled with alkaline phosphatase and 1 mg/ml p-nitrophenyl phosphate as substrate for colorimetric detection at 405 nm. Depletion of antibody reactivity was achieved by preincubating the serum abs at 10 dilution with MC-9 cell extracts prior to the assay. This resulted in an 80% reduction in antibody reactivity to peptide antigen.

Gel Shift Assays

Cell extracts were prepared from 10^7 cells and used in gel shift assays as described previously(20) . Synthetic double-stranded TRE and FIP binding site (FBS) oligonucleotides were used for this assay. The following sequences were used: TRE, 5`-AGC TTA AAA AAG CAT GAG TCA GAC ACC TG-3` and FBS, 5`-GAT CCT AGG CCA CGT GAC CGG-3`. The bound proteins were identified by using a rabbit polyclonal antibody to c-Fos (Medac, Hamburg, Germany) and the rabbit polyclonal anti-mouse FIP described above.

Biosynthetic Labeling and Immunoprecipitation

After IgE sensitization, cells were washed once with Dulbecco's modified Eagle's medium-methionine-free medium (Biological Industry, Beth Haemek, Israel), resuspend in Dulbecco's modified Eagle's medium-methionine-free medium containing 50 µCi/ml [S]methionine (Amersham) and incubated for 1 h at 37 °C. Cells were subsequently activated with DNP-BSA for 60 min as described above.

Immunoprecipitation was essentially as described previously (21) with the following modification: 2.5 times 10^6 cells were lysed by the addition of 500 µl of cold lysis buffer (0.01 M Tris-HCl, pH 7.4, 1% deoxycholate, 1% Triton X-100, 0.1% SDS, 0.15 M NaCl, and 0.25 mM phenylmethylsulfonyl fluoride). Cells were subsequently homogenized, and supernatants were collected after 30 min of microcentrifugation at 4 °C. Antibody to mouse FIP, which had been preincubated in the absence or presence of the FIP peptide, was added to the supernatants. After an overnight incubation at 4 °C, 10 mg of protein A-Sepharose (Sigma) was added, and the mixture was incubated for 3 h at 4 °C with mixing. The recovered immunoprecipitate was washed three times with lysis buffer and once with Tris-EDTA. Proteins were solubilized in boiling Laemmli sample buffer containing 0.5% SDS. The proteins were resolved by 10% SDS-PAGE. Gels were dried and exposed to Kodak X-Omat AR film at -70 °C for varying times. Quantitation of the autoradiography was by densitometric analysis.


RESULTS

Presence of FIP in MC-9 Cells

We were able to confirm the presence of FIP protein in MC-9 cells by incubating S-labeled cell lysate with the antibody to FIP which had been preincubated in the presence or in the absence of the immunogenic peptide (Fig. 1A). Immunoprecipitation revealed a predominant band with the apparent molecular mass of 49 kDa. No bands were detected when the sera used for immunoprecipitation was derived from the preimmune rabbit (data not shown). Specificity of the antibody was further determined by immunoprecipitation from S-labeled cell lysate of the human basophilic precursor cell line KU-812 (16) and the MC-9 cells. Fig. 1B shows that this antibody could recognize only the mouse FIP and not human FIP. In these initial experiments using equal numbers of cells, we observed that more FIP protein was immunoprecipitated from IgE-Ag-activated cells than from nonactivated cells (Fig. 1A), suggesting the possible regulation in response to activation.


Figure 1: Identification of the FIP protein by antibody to mouse FIP in [S]methionine-labeled MC-9 cells. A, [S]methionine-labeled IgE-sensitized MC-9 cells were either exposed for 60 min to DNP-BSA or not (control). FIP protein was identified by immunoprecipitation of cell lysates with antibody to mouse FIP which had been preincubated in the absence or presence of FIP immunogen peptide prior to the addition of the antibody to the cell lysates. Immunoprecipitates were analyzed by SDS-PAGE. B, [S]methionine-labeled cell lysates from either MC-9 or KU812 cells were immunoprecipitated with rabbit antibody to mouse FIP and analyzed by SDS-PAGE. Each sample was run in duplicate. One representative experiment out of three is shown.



Regulation of FIP Synthesis in Response to FcRI Engagement

Kinetic analysis of the synthesis of FIP protein in response to aggregation of the FcRI is shown in Fig. 2. The addition of DNP-BSA to IgE-sensitized cells results in a detectable increase in the levels of FIP within 15 min of addition with maximal levels reached 30 min after antigen addition (4-fold above control). These levels were found to be sustained for at least 120 min after addition of antigen (Fig. 2). This time course of FIP synthesis correlated with our previous results on the increased binding activity of Fos-containing complexes to the FIP DNA binding site(9) .


Figure 2: Kinetics of the expression of FIP in IgE-Ag-stimulated MC-9 cells. Immunoprecipitates of the [S]methionine-labeled FIP. Cells were sampled at the indicated times, lysed, soluble proteins recovered, and incubated with antibody to mouse FIP. Proteins were resolved by SDS-PAGE. One representative experiment of three is shown.



Identification of FIP in the FBS-binding Fos Complex

To confirm that FIP is included in the protein complex which binds to the FBS oligonucleotide, a gel shift assay was performed. As shown in Fig. 3a supershift was obtained when extracts of MC-9 cells were preincubated with the rabbit polyclonal antibody to mouse FIP. A supershift was also obtained when extracts of MC-9 cells were preincubated with antibody to c-Fos. No supershift was obtained with control rabbit serum. These finding suggest that the complex which binds to the FBS (11) oligonucleotide is comprised of at least FIP and Fos.


Figure 3: Identification of FIP in Fos-containing complex bound to the FBS. Cell lysates were prepared from MC-9 cells. Twenty µg of each lysate was incubated with radiolabeled FBS sequence in the absence (control) or presence of a 100-fold excess of unlabeled FBS (compet. FBS) or in the presence of polyclonal antibodies to c-Fos (anti-Fos) or antibody to mouse FIP (anti-FIP) or to normal rabbit serum (NRS), prior to analysis by nondenaturing PAGE and autoradiography. One representative experiment of three is shown.



PKC Regulation of FIP-Fos DNA Binding Activity

We previously described that FIP-Fos and AP-1 DNA binding activities are regulated by PKC(9) . In the present study we investigated which PKC isoenzyme might be involved in the regulation of FIP DNA binding activity. We first determined the concentrations of PKC-alpha, -beta, -, -, and - in IgE-Ag activated or nonactivated MC-9 cells. We focused on these isoenzymes since they were previously reported to be present in cells derived from hematopoietic tissue (22) and in mast cells in particular (13) . The intracellular concentration of each isoenzyme in resting cells is shown in Table 1. No difference in isoenzyme concentration could be found after IgE-Ag activation of the cells. Protein kinase C- was barely detectable in our immunoblots and could not be quantitated. Concentrations were determined by comparison to known concentrations of baculovirus expressed PKC isoenzymes in Western blots using quantitative densitometry under linear conditions. The predominant PKC isoenzymes present in the MC-9 cells were PKC-beta and PKC-alpha. The concentration of PKC-beta was greater than 2-fold of that of PKC-alpha. The concentration of both PKC- and - were approximately 60-fold less than that of PKC-beta. Immunoblots also revealed a down-regulation of all PKC isoenzymes (>90%) by PMA after treatment of the cells for 6 h (data not shown). This was found to be reversible after washing the cells and incubating for 24 h in medium free of PMA.



To study which of the PKC isoenzymes is involved in FIP-Fos and AP-1 DNA binding activities, the PKC isoenzymes were down-regulated by 6 h of treatment with PMA, followed by incubation with an antisense oligonucleotide, directed to the C2 domain of c-PKC(12) , for an additional 48 h. Immunoblots revealed a decrease of 65% ± 16% (n = 3) in the levels of PKC-beta (Fig. 4). Only a slight decrease in the levels of PKC-alpha was observed, while PKC- and - levels were unaffected. Controls treated with sense oligonucleotides were minimally affected (Fig. 4). To determine the role of PKC-beta in the DNA binding activities of FIP-Fos and AP-1, gel shift assays were performed using either a synthetic double-stranded TRE or FBS. We initially confirmed our previous results that aggregation of the FcRI on MC-9 cells could cause an increase in the DNA binding activities of both FIP-Fos and AP-1 complexes(9) . Kinetic analysis of the DNA binding activity revealed that both FIP-Fos (Fig. 5) and AP-1 (data not shown) binding reached a maximum at 15-30 min after antigen stimulation. When PKC-beta was down-regulated, FIP-Fos DNA binding activity decreased by an average of 50% (n = 6) in IgE-Ag-stimulated MC-9 cells (Fig. 6A). In contrast, no effect was observed on the binding activity of AP-1 in the PKC-beta-depleted cells (Fig. 6B). These results suggest that the aggregation of the FcRI in mast cells induces a PKC-beta-dependent signaling pathway for FIP-Fos DNA binding activity.


Figure 4: Down-regulation of PKC-beta by antisense oligonucleotide. MC-9 cells were incubated with PMA for 6 h, washed extensively with growth medium, and further incubated with (ANTISENSE) or without (NOT-TREATED) 10 µM antisense or sense oligonucleotides (SENSE) for an additional 48 h as described under ``Materials and Methods.'' An additional dose of oligonucleotides was added to the culture medium once during the incubation period. One representative experiment of three is shown.




Figure 5: Kinetics of the DNA binding activity of the FIP-Fos complex. Cell lysates were prepared from IgE-sensitized MC-9 cells which were activated (DNP-BSA) or not (control) for the indicated time. Twenty micrograms of each cell lysate was incubated with radiolabeled FBS in the presence (compet. FBS) or absence (control) of 100-fold excess of unlabeled FBS oligonucleotide prior to analysis by nondenaturing PAGE and autoradiography. One representative experiment of three is shown.




Figure 6: The effect of PKC-beta activity on the DNA binding activity of the FIP-Fos complex and of AP-1. A, cell lysates were prepared from IgE-sensitized MC-9 cells which were activated (DNP-BSA) or not after pretreatment with PMA for 6 h and the addition of sense or antisense oligonucleotides as described under ``Materials and Methods.'' Twenty micrograms of each lysate was incubated with radiolabeled FBS in the presence (compet. FBS) or absence of 100-fold excess of unlabeled FBS oligonucleotide. In addition cell lysates were incubated with radiolabeled FBS in the presence of 100-fold excess TRE consensus sequence oligonucleotide (compet. TRE) as an additional control for specificity of FBS binding. Analysis was by nondenaturing PAGE followed by autoradiography. One representative experiment of two is shown. B, cell lysates were prepared from IgE-sensitized MC-9 cells which had been activated (DNP-BSA) or not after treatment as in A. Twenty micrograms of each lysate was incubated with radiolabeled TRE consensus binding sequence in the presence (compet. TRE) or absence of 100-fold excess of unlabeled TRE oligonucleotide, prior to analysis by nondenaturing PAGE and autoradiography. One representative experiment of two is shown.



Regulation of FIP Synthesis by PKC-beta

To further explore the mechanism involved in the PKC-beta-dependent decrease of FIP-Fos DNA binding activity, we measured the expression of FIP in IgE-Ag-activated cells pretreated with PKC-beta sense or antisense oligonucleotides. A significant decrease in the expression of FIP was found in IgE-Ag-activated cells which were treated with the antisense oligonucleotide (Fig. 7A). No decrease was observed in sense oligonucleotide treated cells. Therefore, the decrease in the FIP-Fos DNA binding activity in activated cells where PKC-beta was down-regulated could potentially be attributed to the reduction in the concentration of FIP. Since total recovery of PKC-beta expression could be achieved after washing of PMA and removal of antisense oligonucleotides (data not shown), we assessed the effect of PKC-beta recovery on the expression of FIP. Twenty-four hours after removal of the PKC-beta antisense oligonucleotide from the culture medium, the concentrations of FIP returned to the normal levels observed in control and sense oligonucleotide-treated cells (Fig. 7B). These results suggest that PKC-beta either directly or indirectly regulates the expression of FIP in the MC-9 mast cells.


Figure 7: The effect of down-regulation and recovery of PKC-beta activity on the expression of FIP. A, MC-9 cells were incubated with or without antisense or sense oligonucleotides as described under ``Materials and Methods.'' The [S]methionine-labeled cells were then activated with IgE-Ag. Cells were lysed and soluble proteins immunoprecipitated with antibody to mouse FIP. Proteins were resolved by SDS-PAGE. One representative experiment of three is shown. B, cells were treated or not (control) with PMA for 6 h followed by treatment with PKC-beta sense or antisense for 48 h as described under ``Materials and Methods.'' Following the 48-h incubation with oligonucleotides, the cells were washed and incubated for an additional 24 h without the oligonucleotides to allow recovery of PKC-beta. This was followed by [S]methionine labeling of the cells and activation by IgE-Ag. Cell lysates were prepared and FIP was immunoprecipitated by incubation with antibody to mouse FIP. Proteins were resolved by SDS-PAGE. One representative experiment of three is shown.




DISCUSSION

Our previous studies have described the possible involvement of FIP in regulating AP-1 activity in MC-9 cells when these cells are activated by IgE-Ag(9) . The analysis of the role of FIP was limited in these studies by the unavailability of antibody to FIP. Nevertheless, we defined the presence of FIP complexed to Fos by analyzing the ability of a Fos-containing complex to bind to the FIP-DNA binding site (9) , since Fos alone does not bind to this DNA sequence. In the present study we show that FIP is present in the MC-9 cells by first identifying a FIP clone with 100% homology to mouse USF-2 (10) from a cDNA library derived from IgE-Ag-stimulated MC-9 cells. Second, we identify the presence of FIP protein with antibody generated to a FIP-specific peptide sequence (Fig. 1). We further demonstrate that IgE-Ag stimulation of MC-9 cells regulates the synthesis of FIP protein and that PKC-beta regulates both the synthesis of FIP and its DNA binding activity.

Although PKC-beta was found to be the predominant isoenzyme in MC-9 cells, differential localization of the various PKC isoenzymes may lead to their involvement in the regulation of FIP expression and DNA binding activity. Moreover, the relative enzymatic activity of the individual PKC isoenzymes does not necessarily correlate with their intracellular concentrations. Thus, we cannot exclude the possibility that other isoenzymes of PKC may also participate in regulating the expression and DNA binding activity of FIP. However, our results are conclusive for a role of PKC-beta activity in either directly or indirectly regulating the synthesis of FIP and of FIP DNA binding activity in response to the aggregation of the FcRI.

Protein kinase C-beta plays a major role in the secretory response of mast cells (13) and also links the FcRI to the induction of AP-1 component expression (14) in the rat basophilic leukemia cell line. However in rat basophilic leukemia cells, PKC-alpha is the predominant isoenzyme(14) , while in the murine MC-9 cells, PKC-beta is the most highly expressed. These differences may be species-specific (rat versus mouse), influenced by the state of differentiation, state of retroviral/chemical transformation, or growth conditions, yet PKC-beta regulates transcription factor synthesis in both cell lines. Nevertheless it still remains unclear as to how PKC-beta is capable of regulating the secretory response, expression of FIP, and expression of AP-1 components in mast cells. It could be argued that the calcium influx in response to the aggregation of the FcRI leads to the preferential activation of the calcium-dependent PKC-beta. In contrast, activation of the calcium-independent PKC-, which also is capable of stimulating c-Fos and c-Jun expression but inhibits phosphatidylinositol hydrolysis(23) , might be attenuated in vivo by negative regulatory influences in response to aggregation of the FcRI. Furthermore, differences in the amino acid sequence of these isoenzymes may determine their interactions with other proteins in vivo which may play a role in the regulation of their activity and thereby of cellular responses.

Based on the results of this study we conclude that the induction of FIP synthesis and increased FIP-Fos DNA binding activity, by aggregation of the FcRI, requires the activity of PKC-beta. According to our results the decrease in FIP-Fos DNA binding activity in the antisense oligonucleotide-treated cells could at minimum be partially attributed to the reduction in the level of FIP in these cells. The ability of Fos to bind to other nuclear proteins such as FIP may generate novel complexes that regulate transcription in a receptor-specific manner. Furthermore, formation of receptor-specific complexes may serve to regulate gene transcription in a direct and indirect manner. For the latter, it is well known that the affinity of binding of Fos-Jun to the TRE is greater than that of Jun-Jun(2) . Thus, the formation of FIP-Fos complexes may attenuate the activity of the AP-1 by decreasing the amount of Fos that might be available for association with Jun. Thus, the receptor-specific synthesis of FIP would indirectly control genes whose expression was regulated by AP-1. Protein kinase C-beta would also influence this transcriptional regulation by increasing the formation of FIP-Fos complexes and increasing the DNA binding activity of this complex.

The specificity of the antisense oligonucleotide approach was determined in our system by the specific inhibition of the expression of only PKC-beta and not other isoenzymes and by the inability of sense oligonucleotides (24) to cause a similar effect. However, we cannot exclude the possibility that the effect observed in this study was due to an indirect effect of the antisense oligonucleotides that ultimately resulted in the down-regulation of PKC-beta. As previously mentioned the antisense oligonucleotide was designed to the C2 domain responsible for the calcium dependence of c-PKC(12) . The amino acid sequence of this site is 90% homologous between the murine PKC-alpha and -beta(17, 25) . Despite the high homology there was only a minimal decrease in the level of PKC-alpha, while the expression of PKC-beta was decreased by greater than 60%. This preferential effect of the antisense might be explained by the difference in the concentrations of PKC-alpha and -beta in MC-9 cells. Thus, since PKC-beta is present in these cells at a concentration greater than 2-fold that of PKC-alpha, it is possible that the oligonucleotide which entered the cells could be preferentially bound by the PKC-beta mRNA. Alternatively, the preferential binding of the oligonucleotide to PKC-beta might be explained by differences in the variable regions adjacent to the C2 domains of these isoenzymes that may influence the conformation and availability of these domains.

Examples for the cross-talk between signaling pathways in biological systems are growing in number. The ability of c-Fos to bind to various proteins enables the cross-talk between the enzymes that are activated by receptor stimulation and genes that are activated or inactivated as a consequence of a particular stimulus. It has to be determined whether other stimuli, like growth factors, might initiate an association of c-Fos with c-Jun rather than with FIP. Furthermore, it is possible that the PKC isoenzymes involved in increasing the DNA binding activity of the AP-1 complex differ from that which initiate binding at the FBS. This complexity in regulation of gene expression might be expected in light of the diverse responses initiated by diverse stimuli.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Biochemistry, Hebrew University-Hadassah Medical School, P. O. Box 12272, Jerusalem, 91120, Israel. Tel.: 972-2-758288; Fax: 972-2-411663.

(^1)
The abbreviations used are: IgE-Ag, IgE-antigen; PKC, protein kinase C; FIP, Fos-interacting protein; Zip, leucine zipper; HLH, helix-loop-helix; bZip, basic region Zip; bHLH, basic region HLH; PMA, phorbol 12-myristate 13-acetate; DNP, dinitrophenol; BSA, bovine serum albumin; Tricine, N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine; TRE, TPA responsive element; FBS, FIP binding site.


REFERENCES

  1. Beaven, M. A., and Metzger, H. (1993) Immunol. Today 14, 222-226 [CrossRef][Medline] [Order article via Infotrieve]
  2. Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T., and Karin, M. (1988) Cell 54, 541-552 [Medline] [Order article via Infotrieve]
  3. Rauscher, F. J., III, Sambucetti, L. C., Curran, T., Distel, R. J., and Spielgelman, B. M. (1988) Cell 52, 471-480 [Medline] [Order article via Infotrieve]
  4. Gentz, R., Rauscher, F. J., III, Abate, C., and Curran, T. (1989) Science 243, 1695-1699 [Medline] [Order article via Infotrieve]
  5. Landschulz, W. H., Johnson, P. F., and McKnight, S. L. (1988) Science 240, 1759-1764 [Medline] [Order article via Infotrieve]
  6. Sasson-Corsi, P., Ransone, L. J., Lamph, W. W., and Verma, I. M. (1988) Nature 336, 692-695 [CrossRef][Medline] [Order article via Infotrieve]
  7. Mackgregor, P. F., Abate, C., and Curran, T. (1990) Oncogene 5, 451-458 [Medline] [Order article via Infotrieve]
  8. Hunter, T., and Karin, M. (1992) Cell 70, 375-385 [Medline] [Order article via Infotrieve]
  9. Lewin, I., Nechushtan, H., Qingen, K., and Razin, E. (1993) Blood 82, 3745-3751 [Abstract]
  10. Sirito, M., Lin, Q., Maity, T., and Sawadogo, M. (1994) Nucleic Acids Res. 22, 427-433 [Abstract]
  11. Blanar, M. A., and Rutter, W. J. (1992) Science 256, 1014-1018 [Medline] [Order article via Infotrieve]
  12. Nishizuka, Y. (1992) Science 258, 607-614 [Medline] [Order article via Infotrieve]
  13. Ozawa, K., Szallasi, Z., Kazanietz, M. G., Blumberg, P. M., Mischak, H., Mushinski, J. F., and Beaven, M. A. (1993) J. Biol. Chem. 268, 1749-1756 [Abstract/Free Full Text]
  14. Razin, E., Szallasi, Z., Kazanietz, M. G., Blumberg, P. M., and Rivera, J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7722-7726 [Abstract]
  15. Nabel, G., Galli, S. J., Dvorak, A. M., Dvorak, H. F., and Cantor, H. (1981) Nature 291, 332-334 [Medline] [Order article via Infotrieve]
  16. Baranes, D., and Razin, E. (1991) Blood 78, 2354-2364 [Abstract]
  17. Ashendel, C. L., and Tans, Y. M. (1990) Nucleic Acids Res. 18, 5310-5310 [Medline] [Order article via Infotrieve]
  18. Szallasi, Z., Smith, C. B., Pettit, G. R., and Blumberg, P. M. (1994) J. Biol. Chem. 269, 2118-2124 [Abstract/Free Full Text]
  19. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl Acad. Sci. U. S. A. 74, 5463-5467 [Abstract]
  20. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  21. Kovary, K., and Bravo, R. (1991) Mol. Cell. Biol. 11, 2451-2458 [Medline] [Order article via Infotrieve]
  22. Mischak, H., Kolch, W., Goodnight, J., Davidson, W. F., Rapp, U., Rose-John, S., and Mushinski, J. F. (1991) J. Immunol. 147, 3981-3987 [Abstract/Free Full Text]
  23. Ozawa, K., Yamada, K., Kazanietz, M. G., Blumberg, P. M., and Beaven, M. A. (1993) J. Biol. Chem. 268, 2280-2283 [Abstract/Free Full Text]
  24. Wagner, R. W. (1994) Nature 372, 333-335 [CrossRef][Medline] [Order article via Infotrieve]
  25. Rose-John, S., Dietrich, A., and Marks, F. (1988) Gene (Amst.) 74, 465-471

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.